DelveInsight’s, “Brain Metastases Pipeline Insight 2023” report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Brain Metastases Pipeline Report

• DelveInsight’s Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
• The leading companies working in the Brain Metastases Market include HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Promising Brain Metastases Pipeline Therapies in the various stages of development include 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.
• December 2023: GT Medical Technologies Inc. announced a study of Phase 3 clinical trials for Gamma Tile-Surgically Targeted Radiation Therapy (STaRT). This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRS 3-4 weeks following metastatic tumor resection which is the current standard of care.
• December 2023: H. Lee Moffitt Cancer Center and Research Institute announced a study of early Phase 1 clinical trials for Nivolumab and Ipilimumab. The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.

 

Request a sample and discover the recent advances in Brain Metastases Treatment Drugs @ Brain Metastases Pipeline Outlook Report

 

In the Brain Metastases pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Brain Metastases Overview

Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

 

Find out more about Brain Metastases Therapeutics Assessment @ Brain Metastases Preclinical and Discovery Stage Products

 

Brain Metastases Emerging Drugs Profile

• ANG1005: Angiochem
• Azeliragon: Cantex Pharmaceuticals, Inc.
• AZD3759: Alpha Biopharma Ltd.

 

Brain Metastases Pipeline Therapeutics Assessment

There are approx. 45+ key companies which are developing the therapies for Brain metastases. The Brain Metastases companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III.

 

DelveInsight’s Brain Metastases Pipeline Report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Brain Metastases Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging Brain Metastases Pipeline Therapies @ Brain Metastases Clinical Trials Assessment

 

Scope of the Brain Metastases Pipeline Report

• Coverage- Global
• Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Brain Metastases Companies- HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Brain Metastases Pipeline Therapies- 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.

 

Dive deep into rich insights for new drugs for Brain Metastases Treatment, Visit @ Brain Metastases Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Brain metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Brain metastases– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ANG1005: Angiochem
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Paxalisib: Kazia Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MW151: ImmunoChem Therapeutics, LLC
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. JBI-2174: Jubilant Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Brain metastases Key Companies
21. Brain metastases Key Products
22. Brain metastases- Unmet Needs
23. Brain metastases- Market Drivers and Barriers
24. Brain metastases- Future Perspectives and Conclusion
25. Brain metastases Analyst Views
26. Brain metastases Key Companies
27. Appendix

 

For further information on the Brain Metastases Pipeline therapeutics, reach out to Brain Metastases Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market